{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:54Z","timestamp":1790821554601,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02902-0","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T05:05:35Z","timestamp":1718082335000},"page":"3059-3075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-8554","authenticated-orcid":false,"given":"Mark","family":"Gudesblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bumstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijean","family":"Buhse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myassar","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wilken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"2902_CR1","unstructured":"National Multiple Sclerosis Society. Disease-modifying therapies for MS 2022. https:\/\/www.nationalmssociety.org\/managingms\/treating-ms\/disease-modifying-therapies. Accessed 9 Dec 2022"},{"issue":"3","key":"2902_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40120-022-00349-5","volume":"11","author":"J Burtchell","year":"2022","unstructured":"Burtchell J, Clemmons D, Clemmons J, et al. A targeted literature search and phenomenological review of perspectives of people with multiple sclerosis and healthcare professionals of the immunology of disease-modifying therapies. Neurol Ther. 2022;11(3):955\u201379.","journal-title":"Neurol Ther"},{"key":"2902_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"2902_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077\u201387.","journal-title":"Clin Ther"},{"issue":"17","key":"2902_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"issue":"3","key":"2902_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","volume":"34","author":"F Sellebjerg","year":"2020","unstructured":"Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269\u201380.","journal-title":"CNS Drugs"},{"issue":"2","key":"2902_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000940","volume":"8","author":"JI Fern\u00e1ndez-Velasco","year":"2021","unstructured":"Fern\u00e1ndez-Velasco JI, Kuhle J, Monreal E, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2):e940.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2902_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103921","volume":"63","author":"JA Nicholas","year":"2022","unstructured":"Nicholas JA, Gudesblatt M, Garabedian M, et al. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Mult Scler Relat Disord. 2022;63: 103921.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2902_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184\u201391.","journal-title":"JAMA Neurol"},{"key":"2902_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104400","volume":"68","author":"J Peters","year":"2022","unstructured":"Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400.","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"2902_CR11","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95(14):e1999\u20132008.","journal-title":"Neurology"},{"key":"2902_CR12","doi-asserted-by":"crossref","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012836.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"2902_CR13","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1212\/WNL.0000000000013108","volume":"98","author":"C Tortorella","year":"2022","unstructured":"Tortorella C, Aiello A, Gasperini C, et al. Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology. 2022;98(5):e541\u201354.","journal-title":"Neurology"},{"issue":"6","key":"2902_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.nrl.2018.02.006","volume":"36","author":"LA Rodr\u00edguez de Antonio","year":"2021","unstructured":"Rodr\u00edguez de Antonio LA, Garc\u00eda Casta\u00f1\u00f3n I, Aguilar-Amat Prior MJ, Puertas I, Gonz\u00e1lez Su\u00e1rez I, Oreja Guevara C. Non-inflammatory causes of emergency consultation in patients with multiple sclerosis. Neurologia (Engl Ed). 2021;36(6):403\u201311.","journal-title":"Neurologia (Engl Ed)"},{"key":"2902_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fneur.2017.00116","volume":"8","author":"EA Mills","year":"2017","unstructured":"Mills EA, Mirza A, Mao-Draayer Y. Emerging approaches for validating and managing multiple sclerosis relapse. Front Neurol. 2017;8:116.","journal-title":"Front Neurol"},{"key":"2902_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103946","volume":"63","author":"SE Conway","year":"2022","unstructured":"Conway SE, Healy BC, Zurawski J, et al. COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Mult Scler Relat Disord. 2022;63: 103946.","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 5","key":"2902_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/brain\/awf098","volume":"125","author":"D Buljevac","year":"2002","unstructured":"Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952\u201360.","journal-title":"Brain"},{"key":"2902_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103737","volume":"62","author":"S Satyanarayan","year":"2022","unstructured":"Satyanarayan S, Safi N, Sorets T, et al. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Mult Scler Relat Disord. 2022;62: 103737.","journal-title":"Mult Scler Relat Disord"},{"key":"2902_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103785","volume":"61","author":"C Jakubecz","year":"2022","unstructured":"Jakubecz C, Zhang XS, Woodson S, Serra A, Abboud H. The humoral response to SARS-COV-2 vaccines in MS patients: a case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type. Mult Scler Relat Disord. 2022;61:103785.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"2902_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase\u00a04, non-inferiority trial. Lancet Neurol. 2023;22(7):568\u201377.","journal-title":"Lancet Neurol"},{"key":"2902_CR21","unstructured":"Biogen. Vumerity [Summary of Product Characteristics]. Netherlands2023. p. 2\u20133."},{"key":"2902_CR22","unstructured":"Biogen. Vumerity [Prescribing Information]. Cambridge, MA2023."},{"key":"2902_CR23","unstructured":"Biogen. Data on file."},{"issue":"4","key":"2902_CR24","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","volume":"39","author":"S Wray","year":"2022","unstructured":"Wray S, Then Bergh F, Wundes A, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase\u00a03 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810\u201331.","journal-title":"Adv Ther"},{"issue":"4","key":"2902_CR25","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780\u20139.","journal-title":"Ann Neurol"},{"issue":"19","key":"2902_CR26","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97(19):e1870\u201385.","journal-title":"Neurology"},{"issue":"2","key":"2902_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302.","journal-title":"Ann Neurol"},{"key":"2902_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.msard.2019.01.051","volume":"30","author":"D Golan","year":"2019","unstructured":"Golan D, Wilken J, Doniger GM, et al. Validity of a multi-domain computerized cognitive assessment battery for patients with multiple sclerosis. Mult Scler Relat Disord. 2019;30:154\u201362.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"2902_CR29","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2902_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/1352458513513058","volume":"20","author":"B Teter","year":"2014","unstructured":"Teter B, Agashivala N, Kavak K, Chouhfeh L, Hashmonay R, Weinstock-Guttman B. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis. Mult Scler. 2014;20(7):830\u20136.","journal-title":"Mult Scler"},{"issue":"1","key":"2902_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13311-010-0005-1","volume":"8","author":"KM Galetta","year":"2011","unstructured":"Galetta KM, Calabresi PA, Frohman EM, Balcer LJ. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics. 2011;8(1):117\u201332.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2902_CR32","doi-asserted-by":"publisher","first-page":"20472","DOI":"10.1038\/s41598-022-24312-4","volume":"12","author":"T Pearson","year":"2022","unstructured":"Pearson T, Chen Y, Dhillon B, Chandran S, van Hemert J, MacGillivray T. Multi-modal retinal scanning to measure retinal thickness and peripheral blood vessels in multiple sclerosis. Sci Rep. 2022;12(1):20472.","journal-title":"Sci Rep"},{"issue":"2","key":"2902_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1177\/1352458517740216","volume":"25","author":"G Bsteh","year":"2019","unstructured":"Bsteh G, Hegen H, Teuchner B, et al. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. Mult Scler. 2019;25(2):196\u2013203.","journal-title":"Mult Scler"},{"issue":"2","key":"2902_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1007\/s00415-022-11474-4","volume":"270","author":"S Swinnen","year":"2023","unstructured":"Swinnen S, De Wit D, Van Cleemput L, Cassiman C, Dubois B. Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review. J Neurol. 2023;270(2):1178\u201386.","journal-title":"J Neurol"},{"issue":"6","key":"2902_CR35","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","volume":"15","author":"EH Martinez-Lapiscina","year":"2016","unstructured":"Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15(6):574\u201384.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2902_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40120-020-00223-2","volume":"10","author":"P Repovic","year":"2021","unstructured":"Repovic P, Robertson D, Kresa-Reahl K, et al. Effectiveness of dimethyl fumarate in patients with relapsing multiple sclerosis switching after suboptimal response to glatiramer acetate, including patients with early multiple sclerosis: subgroup analysis of RESPOND. Neurol Ther. 2021;10(1):169\u201382.","journal-title":"Neurol Ther"},{"key":"2902_CR37","unstructured":"Hassanein M, Kaczmarek O, Sethi A, et al. Association between cognition and social role participation among patients with multiple sclerosis. The Consortium of Multiple Sclerosis Centers Annual Meeting 2021."},{"issue":"6","key":"2902_CR38","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/bcp.14658","volume":"87","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Petry C, Mercier F, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021;87(6):2511\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2902_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388.","journal-title":"N Engl J Med"},{"issue":"10","key":"2902_CR40","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1007\/s00415-022-11197-6","volume":"269","author":"G Dorcet","year":"2022","unstructured":"Dorcet G, Mign\u00e9 H, Biotti D, et al. Early B\u00a0cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression. J Neurol. 2022;269(10):5443\u201353.","journal-title":"J Neurol"},{"issue":"6","key":"2902_CR41","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00415-021-10399-8","volume":"268","author":"M Boremalm","year":"2021","unstructured":"Boremalm M, Sundstr\u00f6m P, Salzer J. Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. J Neurol. 2021;268(6):2161\u20138.","journal-title":"J Neurol"},{"key":"2902_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102279","volume":"44","author":"D Baker","year":"2020","unstructured":"Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase\u00a0II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102279.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"2902_CR43","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bpa.12711","volume":"29","author":"J Traub","year":"2019","unstructured":"Traub J, Traffehn S, Ochs J, et al. Dimethyl fumarate impairs differentiated B\u00a0cells and fosters central nervous system integrity in treatment of multiple sclerosis. Brain Pathol. 2019;29(5):640\u201357.","journal-title":"Brain Pathol"},{"issue":"5","key":"2902_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/acn3.411","volume":"4","author":"MD Smith","year":"2017","unstructured":"Smith MD, Martin KA, Calabresi PA, Bhargava P. Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. Ann Clin Transl Neurol. 2017;4(5):351\u20135.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"2902_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000211","volume":"3","author":"SK Lundy","year":"2016","unstructured":"Lundy SK, Wu Q, Wang Q, et al. Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurol Neuroimmunol Neuroinflamm. 2016;3(2):e211.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"2902_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase\u00a0I trial. Ann Neurol. 2008;63(3):395\u2013400.","journal-title":"Ann Neurol"},{"issue":"3","key":"2902_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon \u03b2-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"2902_CR48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835\u201341.","journal-title":"Neurotherapeutics"},{"key":"2902_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103458","volume":"57","author":"A Garjani","year":"2022","unstructured":"Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Mult Scler Relat Disord. 2022;57: 103458.","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"2902_CR50","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990\u20132001.","journal-title":"Nat Med"},{"issue":"12","key":"2902_CR51","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jamaneurol.2021.3599","volume":"78","author":"L Brill","year":"2021","unstructured":"Brill L, Rechtman A, Zveik O, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple scerosis teated wth orelizumab. JAMA Neurol. 2021;78(12):1510\u20134.","journal-title":"JAMA Neurol"},{"key":"2902_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103636","volume":"73","author":"SP Gadani","year":"2021","unstructured":"Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T\u00a0cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021;73:103636.","journal-title":"EBioMedicine"},{"key":"2902_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581.","journal-title":"EBioMedicine"},{"issue":"4","key":"2902_CR54","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861\u201380.","journal-title":"Cell"},{"issue":"10","key":"2902_CR55","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1007\/s00415-023-11935-4","volume":"270","author":"R Spierer","year":"2023","unstructured":"Spierer R, Lavi I, Bloch S, Mazar M, Golan D. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies. J Neurol. 2023;270(10):4632\u20139.","journal-title":"J Neurol"},{"issue":"7","key":"2902_CR56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/13524585231167515","volume":"29","author":"R Capuano","year":"2023","unstructured":"Capuano R, Prosperini L, Altieri M, et al. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs. Mult Scler. 2023;29(7):856\u201365.","journal-title":"Mult Scler"},{"key":"2902_CR57","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.","journal-title":"Front Neurol"},{"key":"2902_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103171","volume":"55","author":"S Epstein","year":"2021","unstructured":"Epstein S, Fong KT, De Jager PL, et al. Evaluation of ocrelizumab in older progressive multiple sclerosis patients. Mult Scler Relat Disord. 2021;55:103171.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02902-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02902-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02902-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:11:48Z","timestamp":1721661108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02902-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2902"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02902-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Gudesblatt: speaker and consulting for Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi Genzyme, Saol Therapeutics, and Teva Pharmaceuticals. Daniel Golan: Speaker and consulting for Bristol Myers Squib, Medison, Merck Serono, Novartis, and Roche. Barbara Bumstead: speaker and consulting for Biogen and BMS. Marijean Buhse: speaker and consulting for Biogen and Genzyme. Myassar Zarif: speaker and consulting for Biogen, BMS, EMD Serono, Horizon, Genentech, Novartis, and Sanofi. Sarah A. Morrow: served on advisory boards for Biogen Idec, EMD Serono, Novartis, Roche, and Sanofi Genzyme; received investigator-initiated grant funds from Biogen Idec, Roche, and Sanofi Genzyme; acted as site PI for multi-center trials funded by BMS, EMD Serono, Novartis, Roche, and Sanofi Genzyme; and received funding from CIHR, MSSC, and NMSS. Dr. Morrow\u2019s new affiliation is Department of Clinical Neurosciences, University of Calgary, Hotchkiss Brain Institute, Calgary, AB, Canada. The affiliation listed in the title was Dr. Morrow\u2019s affiliation at the time of the study. Jacqueline A. Nicholas: has received consultancy fees from Bristol Myers Squibb, EMD Serono, Genentech, MyMSTeam, Novartis, Octave Bio and TG Therapeutics; has received research support from Novartis, Genentech, Alexion, Octave Bio, Sanofi Genzyme, University of Buffalo and PCORI; serves on speakers\u2019 bureau for EMD Serono and TG Therapeutics. Laura M. Hancock: research support from BMS, Clinical & Translational Science Institute and Advancing a Healthier Wisconsin Research and Education Program, and NIH; and speaker honoraria from Can Do MS, the. MS Association of America, and the National MS Society of America. Jeffrey Wilken: nothing to disclose. Nicole Scott, Anne Gocke, James B. Lewin, and Jason P. Mendoza: employees of and hold stock\/stock options in Biogen. Olivia Kaczmarek: nothing to disclose. Joanna Weller: nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted according to local regulations and in compliance with the principles of the Declaration of Helsinki 1964. All instructions, regulations, and agreements of the protocol, and applicable International Conference on Harmonisation guidelines, were adhered to, and the study protocol was approved by the Institutional review board (IRB). Because this was a retrospective cohort study, based on routinely collected clinical data in a coded database, informed consent has been waived by the IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}